Jessica Jones
Payments from drug & device makers
Across 206 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$611
- AbbVie$560
- Pfizer$301
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$296
- Amgen$294
- GSK$292
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $611 |
| AbbVie | 31 | $560 |
| Pfizer | 15 | $301 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $296 |
| Amgen | 17 | $294 |
| GSK | 11 | $292 |
| AstraZeneca | 15 | $287 |
| Lilly USA, LLC | 15 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $133 |
| Bayer | 7 | $111 |
| Sanofi-aventis U.S. LLC | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Paratek Pharmaceuticals, Inc. | 5 | $90 |
| Almatica Pharma LLC | 4 | $79 |
| Boehringer Ingelheim | 4 | $68 |
| Astellas Pharma US Inc | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Novartis | 2 | $44 |
| Viatris Specialty LLC | 2 | $43 |
| Exact Sciences | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Dexcom, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Nevro Corp. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
How this compares
$3,904 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $68,478 |
| OzempicSemaglutide | 41 | $53,250 |
| EliquisApixaban | 40 | $48,029 |
| MounjaroTirzepatide | 17 | $29,608 |
| KerendiaFinerenone | 14 | $22,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $17,906 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $12,640 |
| MyrbetriqMirabegron | 12 | $8,863 |
| EntrestoSacubitril/Valsartan | 11 | $7,424 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,251 |
| Dexlansoprazole DrDexlansoprazole | 15 | $2,794 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $2,225 |
| SynthroidLevothyroxine Sodium | 15 | $1,879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,828 |
| Estradiol | 18 | $1,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $68 | $81,11891 claims |
| Novo NordiskOzempic | $611 | $53,25041 claims |
| PfizerEliquis | $301 | $48,02940 claims |
| Lilly USA, LLCMounjaro | $253 | $29,60817 claims |
| BayerKerendia | $111 | $22,94514 claims |
| GSKTrelegy Ellipta | $292 | $17,90616 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $8,86312 claims |
| NovartisEntresto | $44 | $7,42411 claims |
| AbbVieSynthroid | $560 | $1,87915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Sylva
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.